<DOC>
	<DOCNO>NCT00185588</DOCNO>
	<brief_summary>The purpose study determine optimal safe tolerable dose gemcitabine combination daily twice daily dose PTK/ZK patient unresectable pancreatic cancer . The Phase II part study plan determine antitumor activity regimen effectiveness prevent tumor growth spread .</brief_summary>
	<brief_title>Phase 1-2 Vatalanib Gemcitabine Advanced Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Vatalanib</mesh_term>
	<criteria>Inclusion Criteria Histologically cytologically confirm adenocarcinoma pancreas Unresectable ( due involvement critical vasculature , adjacent organ invasion , presence metastasis ) If &gt; 5 year primary surgery development metastatic disease , separate histological cytological confirmation metastatic disease Primary metastatic lesion within 4 week prior entry study WHO performance status 0 2 ≤ 18 year age Absolute Neutrophil Count ( ANC ) ≥ 1.5 x 10e9/L ( &gt; = 1500/mm3 ) Platelets ( PLT ) ≥ 100 x 10^9/L ( ≥ 100,000/mm3 ) Hemoglobin ( Hgb ) ≥ 9 g/dL Serum creatinine ≤ 1.5 upper limit normal ( ULN ) Serum bilirubin ≤ 1.5 ULN Aspartate aminotransferase ( AST/SGOT ) alanine aminotransferase ( ALT/SGPT ) ≤ 3.0 x ULN OR ≤ 5 x ULN liver metastases present Proteinuria : Negative proteinuria base dip stick reading OR If dip stick read +1 result , total urinary protein ≤ 500 mg measure creatinine clearance ( CrCl ) ≥ 50 mL/min 24hour urine collection Life expectancy ≥ 12 week Ability give write informed consent Exclusion Criteria For `` phase 1 '' portion study : prior gemcitabine therapy . For `` phase 2 '' portion study : prior chemotherapy { except lowdose 5fluorouracil ( 5FU ) radiosensitizer ] Radiotherapy ( RT ) . The site previous RT must progressive disease site disease ) . Prior full field radiotherapy ≤ 4 week prior enrollment OR Limited field radiotherapy ≤ 2 week prior enrollment . Patients must recover therapyrelated toxicity . Prior biologic immunotherapy ≤ 2 week prior registration . Prior therapy antiVEGF agent History presence central nervous system ( CNS ) disease Patients history another primary malignancy ≤ 5 year ( Exception : inactive basal squamous cell carcinoma skin ) Major surgery ≤ 4 week prior enrollment . ( Exception : insertion vascular access device ) Minor surgery ≤ 2 week prior enrollment . ( Exception : insertion vascular access device ) Concurrent use investigational agent patient receive investigational drug ≤ 4 week prior enrollment . Pregnant , breastfeeding , employ effective method birth control . Preexisting peripheral sensory neuropathy functional impairment ( ≥ CTCAE grade 2 neuropathy ) Respiratory compromise due pleural effusion ascites ( ≥ CTCAE grade 2 dyspnea ) QTc &gt; 450 m ( male ) &gt; 470 m ( female ) Uncontrolled high blood pressure History labile hypertension History poor compliance antihypertensive regimen Unstable angina pectoris Symptomatic congestive heart failure Myocardial infarction ≤ 6 month prior registration / randomization Serious uncontrolled cardiac arrhythmia Uncontrolled diabetes Active uncontrolled infection Interstitial pneumonia Extensive symptomatic interstitial fibrosis lung Chronic renal disease Acute chronic liver disease Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption vatalanib Human immunodeficiency virus ( HIV ) infection ( confirm ) , potential interaction vatalanib antiHIV medication HIV infection ( confirm ) judge increase subject risk due pharmacologic activity vatalanib Receiving warfarin sodium ( Coumadin ) similar . Heparin allow . Unwilling unable comply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>